The HR-negative/HER2+ BC subtype and TNBC (basal-like) represent 15–20% and 15% of invasive BCs, respectively, and both are associated with worse prognosis and are considered more aggressive than HR+ subtypes [70]. The gene discussed is ERBB2; the disease is breast cancer.